These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 1654205

  • 1. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors.
    Ishida R, Miki T, Narita T, Yui R, Sato M, Utsumi KR, Tanabe K, Andoh T.
    Cancer Res; 1991 Sep 15; 51(18):4909-16. PubMed ID: 1654205
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives.
    Tanabe K, Ikegami Y, Ishida R, Andoh T.
    Cancer Res; 1991 Sep 15; 51(18):4903-8. PubMed ID: 1654204
    [Abstract] [Full Text] [Related]

  • 3. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M, Wessel I, Jensen LH, Holm B, Oliveri RS, Kenwrick S, Creighton AM, Nitiss JL, Jensen PB.
    Cancer Res; 1998 Apr 01; 58(7):1460-8. PubMed ID: 9537249
    [Abstract] [Full Text] [Related]

  • 4. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
    Morgan SE, Cadena RS, Raimondi SC, Beck WT.
    Mol Pharmacol; 2000 Feb 01; 57(2):296-307. PubMed ID: 10648639
    [Abstract] [Full Text] [Related]

  • 5. Cell cycle progression and chromosome segregation in mammalian cells cultured in the presence of the topoisomerase II inhibitors ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane; ADR-529] and ICRF-159 (Razoxane).
    Gorbsky GJ.
    Cancer Res; 1994 Feb 15; 54(4):1042-8. PubMed ID: 8313360
    [Abstract] [Full Text] [Related]

  • 6. The combination of different types of antitumor topoisomerase II inhibitors, ICRF-193 and VP-16, has synergistic and antagonistic effects on cell survival, depending on treatment schedule.
    Ishida R, Iwai M, Hara A, Andoh T.
    Anticancer Res; 1996 Feb 15; 16(5A):2735-40. PubMed ID: 8917380
    [Abstract] [Full Text] [Related]

  • 7. Effects of the L isomer (+)-1,2-bis(3,5-dioxopiperazine-1-yl)propane on cell survival and cell cycle progression of cultured mammalian cells.
    Traganos F, Darzynkiewicz Z, Melamed MR.
    Cancer Res; 1981 Nov 15; 41(11 Pt 1):4566-76. PubMed ID: 6171341
    [Abstract] [Full Text] [Related]

  • 8. bis(2,6-dioxopiperaxine) derivatives, topoisomerase II inhibitors which do not form a DNA cleavable complex, induce thymocyte apoptosis.
    Onishi Y, Azuma Y, Kizaki H.
    Biochem Mol Biol Int; 1994 Jan 15; 32(1):115-22. PubMed ID: 8012276
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae.
    Ishida R, Hamatake M, Wasserman RA, Nitiss JL, Wang JC, Andoh T.
    Cancer Res; 1995 Jun 01; 55(11):2299-303. PubMed ID: 7757979
    [Abstract] [Full Text] [Related]

  • 11. Development and properties of an etoposide-resistant human leukaemic CCRF-CEM cell line.
    Patel S, Austin CA, Fisher LM.
    Anticancer Drug Des; 1990 Feb 01; 5(1):149-57. PubMed ID: 2156515
    [Abstract] [Full Text] [Related]

  • 12. [Flow cytometric analysis of ICRF-193 influence on cell passage through mitosis].
    Shatrova A, Aksenov ND, Zenin VV.
    Tsitologiia; 2002 Feb 01; 44(11):1068-78. PubMed ID: 12561727
    [Abstract] [Full Text] [Related]

  • 13. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
    Jensen LH, Dejligbjerg M, Hansen LT, Grauslund M, Jensen PB, Sehested M.
    BMC Pharmacol; 2004 Dec 02; 4():31. PubMed ID: 15575955
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Topoisomerase II inhibitor-induced apoptosis in thymocytes and lymphoma cells.
    Kizaki H, Onishi Y.
    Adv Enzyme Regul; 1997 Dec 02; 37():403-23. PubMed ID: 9381984
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH 3T3 fibroblasts and L1210 leukemia cells.
    Markovits J, Pommier Y, Kerrigan D, Covey JM, Tilchen EJ, Kohn KW.
    Cancer Res; 1987 Apr 15; 47(8):2050-5. PubMed ID: 3030540
    [Abstract] [Full Text] [Related]

  • 20. DNA topoisomerase: the mechanism of resistance to DNA topoisomerase II inhibitor VP-16.
    Hong JH.
    Hiroshima J Med Sci; 1989 Dec 15; 38(4):197-207. PubMed ID: 2561562
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.